GIA632 Clinical Trials (2026): 2 Studies for Atopic Dermatitis & Non-segmental Vitiligo
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
2 GIA632 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 2 indications (including Atopic Dermatitis & Non-segmental Vitiligo) and 244 total planned enrollment. 1 GIA632 clinical trial is actively recruiting at 18 U.S. sites across 12 states. Most recent activity: NCT07431177 (Jan 2030).
Where to Participate: All GIA632 Trial Sites in the U.S. (18 sites across 12 states)
Every actively recruiting GIA632trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AL | Cahaba Derm and skin hlth ctr 27 | Birmingham35244 | NCT07431177 | Map |
| CA | MedDerm Associates | San Diego92103 | NCT07431177 | Map |
| CA | Clinical Trials Research Institute | Thousand Oaks91320 | NCT07431177 | Map |
| FL | Encore Medical Research | Hollywood33024 | NCT07431177 | Map |
| FL | Miami Derm and Laser Institute | Miami33173 | NCT07431177 | Map |
| FL | Global Clinical Professionals | St. Petersburg33714 | NCT07431177 | Map |
| IN | Dawes Fretzin Clinical Rea Group | Indianapolis46256 | NCT07431177 | Map |
| MI | Hamzavi Dermatology | Fort Gratiot48059 | NCT07431177 | — |
| MI | Revival Research Institute | Troy48084 | NCT07431177 | Map |
| NE | Skin Specialists PC | Omaha68144 | NCT07431177 | Map |
| NV | Las Vegas Dermatology | Las Vegas89144 | NCT07431177 | Map |
| NY | Equity Medical | The Bronx10455 | NCT07431177 | Map |
| OR | Oregon Medical Research Center | Portland97223 | NCT07431177 | Map |
| TN | International Clinical Research Tennessee LCC | Murfreesboro37130 | NCT07431177 | Map |
| TX | Center for Clinical Studies | Houston77030 | NCT07431177 | Map |
| TX | Austin Inst for Clinical Research | Pflugerville78660 | NCT07431177 | Map |
| TX | ACRC Trials | Plano75024 | NCT07431177 | Map |
| VA | Virginia Clinical Research | Norfolk23507 | NCT07431177 | Map |
GIA632 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | Total |
|---|---|---|---|
| P2 | 1 | 1 | 2 |
Recruiting GIA632 clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07431177 | VITESSA Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo | P2 | Non-segmental Vitiligo | 210 | Mar 2026 |
GIA632 clinical trials by indication
Non-segmental Vitiligo (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07431177 | VITESS | P2 | recruiting | A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo |
Atopic Dermatitis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07220577 | — | P2 | active not recruiting | Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis |
GIA632 pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| VITESS | NCT07431177 | P2 | recruiting | Non-segmental Vitiligo | 210 | — |
All GIA632 trials (2)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07431177 | VITESS | A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo | P2 | recruiting | 210 | Novartis Pharmaceuticals | Mar 2026 |
| NCT07220577 | Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis | P2 | active not recruiting | 34 | Novartis Pharmaceuticals | Nov 2025 |
GIA632 clinical trials: frequently asked questions
- How many GIA632 clinical trials are there?
- 2 GIA632 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants.
- Are GIA632 clinical trials recruiting in 2026?
- Yes — 1 GIA632 trial is actively recruiting in 2026, with 18 U.S. sites across 12 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is GIA632 being studied for?
- GIA632 is being studied for Atopic Dermatitis, Non-segmental Vitiligo. The trials are grouped by indication on this page.
- What phase is GIA632 in?
- GIA632 clinical trials span 2 Phase 2. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors GIA632 clinical trials?
- The lead sponsor across the most GIA632 trials is Novartis Pharmaceuticals. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming GIA632as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: